|
Lilly Adds High-Dose Zepbound to Self-Pay Program, Expands Access to All Approved Strengths
|
Written by: J. Smith |
Hits: 665
|
|
Insulet Launches Omnipod 5 iPhone App with Dexcom G7 Integration for All U.S. Users
|
Written by: J. Smith |
Hits: 416
|
|
Denmark Launches Ambitious Heart Disease Study with Record-Breaking Grant
|
Written by: J. Smith |
Hits: 526
|
|
Zepbound Outperforms Wegovy in Head-to-Head Obesity Trial
|
Written by: J. Smith |
Hits: 760
|
|
Large U.S. Study Finds No Increased Risk of Vision Loss from Semaglutide
|
Written by: J. Smith |
Hits: 705
|
|
CVS Shifts to Wegovy as Preferred Obesity Medication, Raising Questions About Access and Affordability
|
Written by: J. Smith |
Hits: 1345
|
|
Lilly’s Oral GLP-1 Pill Shows Strong Phase 3 Results as Novo Submits Rival for FDA Approval
|
Written by: J. Smith |
Hits: 1192
|
|
Lilly’s Oral GLP-1 Clears Key Trial as Pfizer Exits Race
|
Written by: J. Smith |
Hits: 642
|
|
FDA and Novo Nordisk Warn of Counterfeit Ozempic in U.S. Supply Chain
|
Written by: J. Smith |
Hits: 764
|
|
Liraglutide Reduces BMI in Children Under 12 With Obesity, But Questions Remain
|
Written by: J. Smith |
Hits: 679
|
